News and Trends 10 Nov 2022 Researchers develop new nanoparticle to deliver drugs direct to macrophages How can a drug be delivered exactly where it is needed, while limiting the risk of side effects? The use of nanoparticles to encapsulate a drug to protect it and the body until it reaches its point of action is being increasingly studied. However, this requires identifying the right nanoparticle for each drug according to […] November 10, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Novel branched lipid boosts mRNA delivery to cells A novel branched lipid that is highly stable in storage and is highly efficient in delivering mRNA to cells has been developed. Messenger RNA (mRNA) is a biological molecule that transfers the information coded by genes in the nucleus to the cytoplasm for protein synthesis by ribosomes. mRNA sequences can be designed to encode specific […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Looking for cancer clues? Copper may open new drug treatment doors For cancer cells to grow and spread around the human body, they need proteins that bind copper ions. New research about how cancer-related proteins bind the metal and how they interact with other proteins may open up potential new drug targets in the fight against cancer. Human cells need small amounts of the metal copper […] November 10, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 New radiopharmaceutical shrinks prostate cancer tumors Researchers in Japan and Germany say a radiopharmaceutical treatment targeting a prostate-specific membrane antigen effectively shrinks prostate tumors in mice. The team reported the anti-cancer treatment zeroes in on tumor cells with ‘laser precision.’ Recent developments, such as targeted α-therapies as a type of theranostics, are trying to tackle cancer. Theranostics is a one-two punch […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Does covid vaccination boost cancer treatment? Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. It was feared that vaccination against Covid-19 could reduce the success of cancer treatment or cause severe side effects. However, a recent study by the universities of Bonn, Germany, and Shanxi, China, say this isn’t the case. According […] November 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Study shows enhanced drug delivery to the brain In a study recently published in the journal Nature Biomedical Engineering, Japanese researchers used a method called “lasso-grafting” to design therapeutics with enhanced longevity and brain penetration. Cell growth and repair are stimulated by biomolecules known as cytokines and growth factors. Unfortunately, delivering adequate concentrations of these molecules to the brain for treating neurological conditions […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Hormone discovery could predict long term health of men Researchers have discovered the vital role of INSL3, a hormone that develops in men during puberty, which provides an early prediction of whether they could develop certain diseases in later life. Scientists from the University of Nottingham in the U.K. have discovered that the novel insulin-like peptide hormone, INSL3, is consistent over long periods of […] November 8, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022 EMPA-KIDNEY trial meets primary endpoint in trial for drug to treat chronic kidney disease A phase 3 clinical trial, EMPA-KIDNEY, met its primary endpoint showing a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD). When treated with Jardiance (empagliflozin), the risk of kidney disease progression or cardiovascular death was significantly reduced by 28% versus placebo. The results were announced today during the American Society of […] November 4, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 4 Nov 2022 Optibrium and Lhasa Limited study published on predictive modelling for enzymes A peer reviewed study published in the Journal of Medicinal Chemistry has been published by Optibrium and Lhasa Limited that shows advance predictive modelling for drug-metabolizing enzymes. The companies are two of the leading developers of software and artificial intelligence (AI) solutions for drug discovery and development. In the paper, ‘Predicting Regioselectivity of AO, CYP, […] November 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Trial and new drug for Tourette Syndrome after $250M after funding round completed A phase 3 clinical trial and the potential commercialization of a new class of drug for patients with Tourette Syndrome have been funded after an upsized and oversubscribed $250 million series D funding round. Emalex Biosciences announced the closing today (November 3) of the round that was led by Bain Capital Life Sciences with participation […] November 3, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Senescent cells as vaccines against cancer? Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumor. This means immune cells cannot reach the cancer cells to remove them. The scientific community has been working to increase the effectiveness of […] November 3, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 Authorization given to BeiGene’s chemo-free treatment option for lymphoma Marketing authorization has been granted to a drug to treat relapsed/refractory (R/R) marginal zone lymphoma (MZL) without chemotherapy, it was announced today (November 2). The European Commission (EC) gave the authorization to biotech company, BeiGene, for Brukinsa (zanubrutinib), which treats adults with the condition who have received at least one prior anti-CD20-based therapy. The approval […] November 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email